HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Year After US FDA Public Hearing: CBD Demand Soars Along With Need For Safety Data

Executive Summary

US cannabis research funding of $189m, growing 65% since 2016, isn’t keeping pace with demand for CBD products with sales projected to surpass $20bn by 2024, says the Collaborative for CBD Science and Safety. It urges industry to accelerate R&D and FDA to move forward with a regulatory framework.

You may also be interested in...



Without US CBD Guidance, Low-Quality Supplements, State Rules Hurt Industry

Responsible CBD supplement marketers are disadvantaged against bad actors with products taking up shelf space in “disloyal” retailers as federal regulatory limbo drags on, says nutritional science expert Duffy McKay. Patchwork of state regulations on CBD also create challenges.

Safety First For Perrigo In CBD Market; ‘Long-Term’ Play Starts With Clinical Trials

Perrigo’s clinical trials on CBD likely will take years before resulting products help bring order to the market. During earnings presentation, CEO Murray Kessler says the trials aren’t intended to establish claims for CBD but are more a long-term effort to provide data to FDA.

With CBD Products Unlawful, FDA Enforcement Policy Guidance Has No Economic Significance

As draft guidance receives OMB review, FDA’s determination of no economic significance reflects its official position that the thousands of supplements, food and personal care products containing CBDs available in the US are unlawful.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel